This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 5mg | $120 | 3-6 Days |
| 10mg | $200 | 3-6 Days |
| 25mg | $320 | 3-6 Days |
| 50mg | $500 | 3-6 Days |
| 100mg | $690 | 3-6 Days |
| 250mg | $1030 | 3-6 Days |
| 500mg | $1450 | 3-6 Days |
Cat #: V5225 CAS #: 1642581-63-2 Purity ≥ 99%
Description: Glumetinib (SCC244; SCC-244; Gumarontinib) is a novel, potent and highly selective c-Met kinase inhibitor (IC50 = 0.42 nM.) with antitumor activity. Remarkably selective compared to 312 other tested protein kinases, glumetinib demonstrated subnanomolar potency against c-Met kinase activity. This makes it one of the most selective c-Met inhibitors currently available. Additionally, the c-Met-dependent neoplastic phenotype of tumor and endothelial cells is suppressed by this inhibitor, which profoundly and specifically inhibits c-Met signal transduction.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 459.4838 |
|---|---|
| Molecular Formula | C21H17N9O2S |
| CAS No. | 1642581-63-2 |
| Storage | Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Synonyms | SCC-244; SCC244; SCC 244; Gumarontinib. |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.1764 mL | 10.8818 mL | 21.7636 mL | 43.5271 mL |
| 5mM | 0.4353 mL | 2.1764 mL | 4.3527 mL | 8.7054 mL |
| 10mM | 0.2176 mL | 1.0882 mL | 2.1764 mL | 4.3527 mL |
| 20mM | 0.1088 mL | 0.5441 mL | 1.0882 mL | 2.1764 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.



































